New combo therapy targets Hard-to-Treat cancers with KRAS mutation
NCT ID NCT05358249
First seen Oct 31, 2025 · Last updated May 18, 2026 · Updated 23 times
Summary
This study is for people with advanced solid tumors (like lung or colorectal cancer) that have a specific genetic change called KRAS G12C. It tests a new drug, JDQ443, combined with other treatments to see if they are safe and can shrink tumors. About 74 adults will take part. The goal is to find better options for cancers that have stopped responding to standard therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NYU School of Medicine
New York, New York, 10015, United States
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.